CRScube Inc. awarded ISO 27001 certification

Seoul 4 January 2019 - CRScube Inc. has gained its ISO 27001 certificate, the worldwide standard for information security, demonstrating the company's commitment to handling clients' clinical data safely and securely.

The externally accredited certification has been awarded by trusted international testing agency DNV GL Business Assurance UK Limited.

Benefits of being ISO 27001 certified include helping to tighten, improve and secure 3rd party supplier contracts and management, as well as facilitating the process of providing eClinical Solutions to multi parties engaged in complex clinical trials.

This certification now places CRScube Inc. amongst a limited number of clinical research solution providers that have achieved this prestigious certification.

Regulatory bodies in clinical research are increasingly recognising the value of the ISO 27001 certification, with many jurisdictions waiving certain security auditing requirements if the relevant parties are certified.

"As the only clinical research solutions provider that is accredited to offer ISO 27001 certification in Asia, CRScube Inc. is uniquely placed to demonstrate our utmost care on customers' data, and the compliance against international standards."

Share via

See CRScube in action

Book a demo

Explore how our platform will elevate your team and clinical trial management.

Get insights straight to your inbox

Explore our knowledge base

Stay in-the-know with regular updates and industry opinions from our expert team.

See all resources

Featured resources

Modern safety reporting in a legacy world – How cubeSAFETY compares, according to CRScube’s COO

Safety reporting is moving beyond simple adverse event collection. The future lies in intelligent risk detection and frictionless data capture.

Electronic safety reporting in clinical trials: What sponsors need to know

For sponsors and CROs, it is crucial to understand the implications of the full enforcement of ICH E2B(R3) standards, especially as it impacts both pre- and post-authorization submissions.